×
Resources » Webinars
Email to GenScript

2017 Webinar Series

Our webinar series features 30-45 minute, online seminars followed by 15 minutes Q&A, which are specially designed to highlight strategies, techniques, services, and products that can streamline your research and help you avoid common pitfalls in your experimental designs.

Register Today! All registrants will receive a link to the recording of the presentation.

Click a title below to jump to the full webinar abstract

Title Register
Using High Throughput Antibody Screening Approaches to Accelerate Drug Discovery
April 5, 2017/
9:00 AM EST
Or 2:00 PM EST
Integrated Antibody Drug Discovery: Lead Generation, Characterization and Optimization
April 12, 2017/
9:00 AM EST
Or 2:00 PM EST
A Guide to CRISPR/Cas9 Delivery: How to Maximize Your Editing Efficiency
April 18, 2017/
11:00 AM EST


Using High Throughput Antibody Screening Approaches to Accelerate Drug Discovery

Are you currently working on a Therapeutic Antibody project and looking for ways to accelerate your program? If yes, this webinar may be for you.

 

April 5, 2017

 
Register 2:00 PM EST

The demand for high affinity antibodies has been steadily increasing over the last few years and enhanced throughput of antibody generation is critical in accelerating the antibody screening process. GenScript has addressed the challenges in high throughput (HTP) antibody generation with a new service that allows the production and purification of recombinant antibodies in an end-user friendly format. This new service combines GenScript's expertise in HTP gene synthesis and transient expression technologies. And it is designed to help researchers scale quickly from promising leads in order to accelerate their therapeutic antibody discovery. Attend this webinar to learn more about the benefits and applications of high throughput antibody screening approaches including a review of case studies.

Presented by: Brady Wu, PhD. Director of Protein Production Department, GenScript

Integrated Antibody Drug Discovery: Lead Generation, Characterization and Optimization

Therapeutic antibody drugs show significant growth rate. Within oncology research alone, more than 20 therapeutic antibody drugs received FDA

 

April 12, 2017

 
Register 2:00 PM EST

approval for new treatments or indications during 2015 and 2016. In addition, more than 300 therapeutic antibody drugs are in ongoing clinical trials. Driven by the increase in biomarker discovery, more therapeutic antibody drugs are set to enter the market with increased competition. Therefore, to maximize the success of therapeutic antibody drug development, it is essential to thoroughly vet antibody drug candidates at every step of the process. Join this interactive webinar to learn more about therapeutic lead generation, lead characterization and lead optimization. We will discuss cutting edge high throughput screening platforms to guide hybridoma clone selection and examine characterization technologies required for rational selection of lead therapeutic antibody drug candidates. We will also review current platforms for lead optimization, including humanization and antibody affinity maturation. Ultimately, attendees will understand how these approaches integrate with both upstream and downstream therapeutic antibody drug discovery methodologies.

Presented by: Liusong Yin, PhD. Vice Director of Antibody Department, GenScript

A Guide to CRISPR/Cas9 Delivery: How to Maximize Your Editing Efficiency

While CRISPR/Cas9 editing is utilized in a wide variety of cell types, editing efficiency continues to pose a challenge to researchers. Join Dr. Allison

 

April 18, 2017

 

Mayle, as she shares best practices for increasing CRISPR/Cas9 editing efficiency. Viewers will learn discover online tools to aid in CRISPR/Cas9 design and delivery, and tips for optimizing your CRISPR/Cas9 experiments.

In this webinar, Dr. Mayle will review the factors influencing genome editing, including target sequence selection and CRISPR/Cas9 delivery methods. A comparison of plasmid and viral vector delivery will be provided, as well as an introduction to DNA-free CRISPR/Cas9 ribonucleoprotein reagents. Additionally, Dr. Mayle will cover best practices for CRISPR knock-in mutagenesis via homology-directed repair (HDR) and applications available from new Cas9 protein variants.

Presented by: Allison Mayle, PhD. Gerstner Sloan-Kettering Teaching Fellow, Memorial Sloan Kettering Cancer Center

Click on a webinar title below to watch the webinar and download a pdf of the presentation

 
*
*
*
*